Search clinical trials for: Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear

Total 21 results

Allergan

Completed

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

Dry Eye Syndrome

United States
Allergan

Completed

Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects

Dry Eye Syndrome

United States
Optometric Technology Group Ltd
Allergan

Completed

Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers

Dry Eye Syndrome

United Kingdom
Allergan

Completed

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

Dry Eye Syndrome

United States
Allergan

Completed

Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

Dry Eye Syndromes

Canada, Australia
Allergan

Completed

Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery

Dry Eye Syndrome

United States
Allergan

Completed

A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery

Bilateral LASIK Surgery

Australia, Canada
University of Florida

Completed

Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome

Dry Eye Syndromes

United States
Allergan

Completed

A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

Dry Eye Syndromes | Keratoconjunctivitis Sicca

France, United Kingdom
Allergan

Completed

A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease

Dry Eye Disease

France, Spain, Russian Federation, Belgium, Germany, Italy, United Kingdom, Australia
Allergan

Completed

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

Dry Eye Syndromes

United States
Wills Eye

Recruiting

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

Rhegmatogenous Retinal Detachment | Proliferative Vitreoretinopathy

United States
Allergan

Completed

A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief

Dry Eye Syndromes

United States
Fundação Altino Ventura

Completed

Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis

Conjunctivitis, Viral

Brazil
Bispebjerg Hospital
Rigshospitalet, Denmark

Unknown

Safe Excipient Exposure in Neonates and Small ChildreN (SEEN)

Pediatric | Neonatal | Excipient Exposure
University of Colorado, Denver

Terminated

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

Open Angle Glaucoma

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

Healthy
Nina Bhardwaj
Cancer Research Institute, New York City; Ludwig Institute for Cancer Research and other collaborators

Completed

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Melanoma

United States
Keimyung University Dongsan Medical Center
Chong Kun Dang Pharmaceutical Corp.

Unknown

Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract (FOREVER)

Ventricular Premature Complexes | Outflow Tract | Carvedilol

Korea, Republic of
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States

3

Subscribe